Condition: Chronic Spontaneous Urticaria (CSU) · Sponsor: Novartis Pharmaceuticals
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderate to severe chronic spontaneous urticaria (CSU) inadequately controlled by sgH1-AHs.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Allervie Clinical Research | Birmingham, Alabama, United States | Recruiting |
| Cahaba Derm and skin hlth ctr 27 | Birmingham, Alabama, United States | Recruiting |
| Research Solutions of Arizona | Litchfield Park, Arizona, United States | Recruiting |
| Peak Dermatology | Payson, Arizona, United States | Recruiting |
| Premier Allergy Asthma And Immunology | Phoenix, Arizona, United States | Recruiting |
| Avacare Center for Dermatology | Phoenix, Arizona, United States | Active Not Recruiting |
| Orso Health | Scottsdale, Arizona, United States | Recruiting |
| Clin Trial Inst of Northwest AR | Fayetteville, Arkansas, United States | Recruiting |
| Acuro Research Inc | Little Rock, Arkansas, United States | Recruiting |
| First OC Dermatology | Fountain Valley, California, United States | Recruiting |
| Ctr for Dermatology Clinical Res | Fremont, California, United States | Recruiting |
| Allergy and Asthma Specialists Group | Huntington Beach, California, United States | Recruiting |
+ 118 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06868212